The next generation of automated microarray platforms for a multiplexed CYP2D6 assay

Phillip Kim, Yung Kang Ken Fu, Vijay Mahant, Fareed Kureshy, Gary Hardiman, Jacques Corbeil

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

One recent advance and fundamental shift in medicine has been the advent of personalized medicine. Improvements in DNA microarray technology have generated data on a scale that, for the first time, permits detailed scrutiny of the human genome, thereby providing the infrastructure to understand the genetic basis of diseases. These advances have the potential to enhance healthcare management by improving disease diagnosis and implementing treatments adapted to each patient. The traditional approach of “one drug fits all” is no longer acceptable. The advent of custom optimization of drugs and dosages results in better treatment efficacy and enhanced safety [1,2]. The emergence of pharmacogenomics has provided a basis with which to evaluate individual variations in response to treatments. Pharmacogenetic testing aims at determining the underlying genotypic and phenotypic differences in the pharmacodynamics and pharmacokinetics of drug metabolism and, as a result, will become an integral part of the therapeutic monitoring and health management of patients.

Original languageEnglish
Title of host publicationBiochips as Pathways to Drug Discovery
PublisherCRC Press
Pages97-108
Number of pages12
ISBN (Electronic)9781420015607
ISBN (Print)9781574444506
Publication statusPublished - 01 Jan 2006
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)
  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'The next generation of automated microarray platforms for a multiplexed CYP2D6 assay'. Together they form a unique fingerprint.

Cite this